(Total Views: 580)
Posted On: 05/27/2022 12:59:29 AM
Post# of 148936
Quote:
Conclusions: These studies suggest that mTNBC pts [patients] dosed with leronlimab had high clinical benefit, i.e. longer PFS [progression free survival] & OS [overall survival] with few TEAEs [treatment emergent adverse events], and leronlimab resulted in a drop in circulating TACs [tumor associated cells] in the majority of pts [patients] correlating with early therapy response.
(4)
(0)Scroll down for more posts ▼
